Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + nivolumab in pediatric and young adult relapsed/refractory lymphoma
NL-OMON58744Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab and nivolumab in classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose / recommended phase 2 dose and 3 more. Started Sep 2023; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
classical Hodgkin lymphoma (cHL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON58744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58744.